The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...

14, 2022 — Results from a phase 3 clinical indicate that the oral drug mitapivat is safe and effective for treating adults with pyruvate kinase deficiency, a ... Aug. 15, 2024 — Over half of ...

Etavopivat is an oral selective pyruvate kinase-R activator that has been awarded fast track and orphan status by the FDA, and along with a phase 2/3 HIBISCUS trial in SCD is also in a follow-up ...

Meanwhile, there are a couple of orally-active pyruvate kinase R activators from Forma Therapeutics and Agios – etavopivat and mitapivat, respectively – in mid-stage development, and Pfizer ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

SG Americas Securities LLC grew its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 796.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 54,921 shares of the ...

Pyruknd won its first approval in 2022 for pyruvate kinase (PK) deficiency, marking the first drug approved to treat the disease. The vaccine was previously approved for use in females who are 9 ...

Researchers have developed a new method for growing T cells in the lab, allowing them to survive longer and fight cancer more effectively. This advancement, detailed in Cell Metabolism, could ...